---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-066091"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-07-07T23:59:59+00:00"
generated_at: "2026-05-18T09:20:28.733922+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics cuts 51% of workforce; CFO and CDO to depart

## Summary
- Board approved reduction in force of ~51% of employees; expects $3.7M in severance costs.
- CFO Morgan Conn to depart effective July 11; SVP Finance Douglas Carr named interim principal financial officer.
- Chief Development Officer Adrienne Farid to depart effective July 31.
- Workforce reduction substantially complete by end of Q3 2025; company focusing on highest-potential programs.

## SEC filing metadata
- accession: 0001104659-25-066091
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/0001104659-25-066091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/tm2519717d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-066091
- JSON: https://secwatch.observer/filing/0001104659-25-066091.json
- Plain text: https://secwatch.observer/filing/0001104659-25-066091.txt

## Key facts
- Restructurings & Charges
  Century Therapeutics, Inc. announced a restructuring with charges of approximately $3.7 million (approximately 51%).
  - Type: restructuring
  - Charge: approximately $3.7 million
  - Headcount: approximately 51%
  source text: On July 1, 2025, the Board of Directors (the “ Board ”) of Century Therapeutics, Inc. (the “ Company ”) approved a reduction in force as part of a broader effort to right size the organization to focus on programs with the highest potential for transformational value. The Company expects to implement a net reduction of its employee headcount by approximately 51% (the “ RIF ”). As part of the RIF, the Company estimates that it will incur charges of approximately $3.7 million for severance and other employee termination-related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/0001104659-25-066091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.